Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Wei Ding, Betsy LaPlant, Timothy G. Call, +32

Blood

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation

Mamta Gupta, Jing Han, Mary Stenson, +6

Blood

GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features

Tianjiao Wang, Andrew L. Feldman, David A. Wada, +16

Blood

Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression

Shaji Kumar, Thomas E. Witzig, Michael Timm, +5

Blood

Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells

Asish K. Ghosh, Tait D. Shanafelt, Amelia Cimmino, +12

Blood

Prognostic value of angiogenesis in solitary bone plasmacytoma

Shaji Kumar, Rafaël Fonseca, Angela Dispenzieri, +8

Blood

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Mamta Gupta, Andrea E. Wahner Hendrickson, Seong Seok Yun, +14

Blood

Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

Vijay Ramakrishnan, Michael Timm, Janine Haug, +6

Oncogene

Hematological MalignancyCommon Anti-myeloma DrugsSignificant Anti-myeloma ActivityMedicinePharmacology +4

Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma

Shaji Kumar, Thomas E. Witzig, Angela Dispenzieri, +8

Leukemia

Hematological MalignancyThalidomide TherapyMedicineMalignant Blood DisorderHematology +7

Bi‐directional activation between mesenchymal stem cells and CLL B‐cells: implication for CLL disease progression

Wei Ding, Grzegorz S. Nowakowski, Traci R. Knox, +13

British Journal of Haematology

Cell TherapyAdult Stem CellImmunologyCll B‐cellsCell Death +14